Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 18/20 | 0.53 |
| ▸ | PPARA | Q07869 | 3/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2823300 | 0.93 | PTGDR2 (0.49) | PTGDR2PPARDPPARAPPARG | |
| SCHEMBL2068429 | 0.91 | PTGDR2 (0.53) | PTGDR2PPARDPPARAPPARG | |
| SCHEMBL2068077 | 0.89 | PPARD (0.68) | PPARDPPARAPPARG | |
| SCHEMBL2828703 | 0.86 | PPARD (0.49) | PTGDR2PPARDPPARAPPARG | |
| SCHEMBL2068612 | 0.85 | PTGDR2 (0.56) | PTGDR2PPARDPPARAPPARG | |
| SCHEMBL2068744 | 0.84 | PPARA (0.41) | PTGDR2PPARDPPARAPPARG | |
| SCHEMBL2070933 | 0.84 | PPARD (0.50) | PTGDR2PPARDPPARAPPARG | |
| SCHEMBL2069995 | 0.82 | PPARD (0.60) | PTGDR2PPARDPPARAPPARG | |
| SCHEMBL12646775 | 0.82 | PPARD (0.50) | PPARDPPARAPPARG | |
| SCHEMBL2069047 | 0.82 | PPARD (0.59) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968723-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-06-28 | — | — | US | claimed |
| EP-1745003-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-10-27 | — | — | EP | claimed |
| US-20090209588-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2009-08-20 | — | — | US | claimed |
| EP-1745003-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2007-01-24 | — | — | EP | claimed |
| WO-2005105726-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | claimed |
| US-7968723-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968723-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-06-28 | — | — | US | disclosed |
| EP-1745003-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-10-27 | — | — | EP | disclosed |
| US-20090209588-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2009-08-20 | — | — | US | disclosed |
| US-20090209588-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2009-08-20 | — | — | US | disclosed |
| EP-1745003-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005105726-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209588-A1 | Novel compounds, their preparation and use | PPARG, PPARD, GPR119 | PTGDR2 492/4885PPARD 2/4885PPARA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.